“While orphan drugs’ share of the $880-billion global pharmaceuticals market remains small—at $50 billion as of the end of 2011, or just 6% of the total—their growth curve has been steep. Thomson Reuters reports that between 2001 and 2010, orphan drugs posted a compound annual growth rate of 25.8%, outstripping the 20.1% CAGR returned by a matched non-orphan control group. With these kinds of eye-popping profits being raked in by orphan drug makers, the investment world has taken notice.”
http://www.caseyresearch.com/cdd/orphans-adding-company-value-in-the-biotech-space
Did you like this?
Tip Freedomwat.ch Staff with Bitcoin
Tip Freedomwat.ch Staff with Bitcoin
Related posts:
Sony's credit rating heads toward junk pile
11 Years After 9/11, It's Time to End the War on Terror
Luke Rudkowski Questions Larry Silverstein On WTC 7 [2011]
America's Internal Checkpoints
Europe Sinks ... As Predicted
Secret backdoors found in firewall, VPN gear from Barracuda Networks
FBI terrorizes anarchists for refusing to testify before grand jury
The Secret Plot to Prop Up the Municipal Bond Market
Save Your Swiss Gold – Peter Schiff’s Message to Switzerland
Companies Tell Employees to Find Their Own Health Insurance Policies
TSA hires a priest excluded from clergy for child molestation
Federal court dismisses Firearms Freedom Act
Two white Texas officers fired for beating black woman over $150 traffic ticket
VPNFilter malware infecting 500,000 consumer devices is worse than we thought
Obama Top Adviser Robert Gibbs Justifies Murder of 16 Year Old